Bloom announces the launch of its products in the UK in early 2026, extending its presence in Europe with New Garden Pharma as exclusive manufacturer

LONDON–(BUSINESS WIRE)–The Bloom Brand, an established U.S. leader in the cannabis vape industry, is making its international debut in the United Kingdom through an exclusive partnership with New Garden Pharma, a major European player in the EU GMP-compliant cannabis market. Together, the two companies will launch Bloom’s award-winning vaporizer lines, Classic and Live, in the United Kingdom during the first quarter of 2026.

This milestone marks Bloom’s first expansion into the international market; the company will continue its global growth strategy in other European markets in 2026 and beyond. As a result, patients in the United Kingdom will have access to Bloom’s proprietary, high-end formulations and devices.

For more than ten years, Bloom has been building a solid reputation by offering cutting-edge, terpene-rich products combined with reliable technology. The brand is an established leader in key markets, including the states of California, Illinois, Florida, Michigan, Missouri, New Jersey, New Mexico, New York, and Virginia.

« »This launch in the U.K. market is a major step toward fulfilling our mission: to reshape the global cannabis experience,« said Ovidiu (David) Chiorpec, Bloom's director of business development. " »We have spent more than ten years building a brand that patients trust in the U.S. market, and we look forward to offering consumers in the United Kingdom a new level of excellence and sophistication in the vaping industry."

New Garden Pharma, the medical subsidiary of New Garden Group, has earned a reputation for trust in the European market for cannabis-related product manufacturing, combining a unique supply chain model with extensive experience in regulatory compliance and market expansion. The company can leverage its established infrastructure across the continent to successfully launch Bloom in the UK market, ensuring compliance, efficiency, and scalability across all channels.

« »We are delighted to welcome Bloom to the U.K. market,« said Alexey Brylev, CEO of New Garden Group. " As an established player in the European medical cannabis markets, we bring the expertise in EU GMP, knowledge of local markets, and regulatory know-how needed to help global brands succeed. »This partnership reflects our mission: to offer world-class products to European patients and to raise the bar even higher for quality, safety, and innovation across the continent.”

For more information, visit thebloombrand.com or Instagram (@bloomforthepeople) and newgardenpharma.com.

The text of the press release resulting from a translation must in no way be considered as official. The only authentic version of the press release is the one in its original language. The translation must always be compared with the source text, which will be the legal precedent.

Contact

Press contact:

Allison Pankow – Marketing Director, Bloom | [email protected]

Contact New Garden Pharma:

Delia Flanagan – Business Development Manager | [email protected]